Kidney Outcomes with SGLT2 Inhibitors vs Other Diabetes Drugs
Author Information
Author(s): Xiao Xiang, Ji Shuming, Zheng Tao, Wang Tianzhu, Jiang Dapeng, Liu Fang
Primary Institution: West China Hospital of Sichuan University
Hypothesis
This study aimed to investigate the association between the utilization of SGLT2 inhibitors in real-world settings and kidney outcomes in patients with type 2 diabetes and chronic kidney disease in mainland China.
Conclusion
SGLT2 inhibitors have shown favorable effects on kidney prognosis in patients with type 2 diabetes and chronic kidney disease in mainland China.
Supporting Evidence
- Patients using SGLT2 inhibitors had a 65% lower risk of kidney composite endpoint events compared to those using other glucose-lowering drugs.
- The mean eGFR decline slope for the SGLT2i group was significantly slower than that for the oGLDs group.
- Significant differences in eGFR decline were observed across various patient subgroups.
Takeaway
This study found that using a specific type of diabetes medication called SGLT2 inhibitors helps protect the kidneys better than other diabetes medications.
Methodology
A retrospective cohort study analyzing electronic medical records of patients with type 2 diabetes and chronic kidney disease.
Potential Biases
Unknown confounding factors may have influenced the results due to the retrospective design.
Limitations
The study's findings may not be generalizable to all regions of China and did not explore SGLT2i dosage.
Participant Demographics
Average age was 62 years, with 65.8% males.
Statistical Information
P-Value
p<0.001
Confidence Interval
95% CI: 4.73–5.15
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website